Results of ECHELON-2 phase III trial of Adcetris for CD30-expressing peripheral T-cell lymphomas is presented at ASH and published in The Lancet.- Seattle Genetics + Takeda

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced that data from the ECHELON-2 phase III clinical trial will be presented in an oral session at ASH. Adcetris (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) is effective in extending progression-free survival (PFS) and overall survival (OS) with a safety profile comparable to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), a current standard of care in patients with CD30-expressing peripheral T-cell lymphomas (PTCL).

See- "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial"-Steven Horwitz, MD, Prof Owen A O'Connor, MD ,Prof Barbara Pro, MD, Published:December 03, 2018DOI:https://doi.org/10.1016/S0140-6736(18)32984-2.